The US Food and Drug Administration (FDA) announced on its Twitter account that it will temporarily allow Juul e-cigarette products to remain on the American market.
On the morning of July 6th, at 7:53 AM US time, the FDA announced on Twitter that it has temporarily suspended the marketing denial order against Juul. According to the FDA, "on July 5th, 2022, the FDA administratively paused the marketing denial order due to unique scientific issues in Juul's application, requiring additional review." The FDA stated that the marketing denial order against Juul will be temporarily suspended during the additional review period, but will not be revoked.
The FDA has stated on Twitter that all electronic nicotine delivery systems (ENDS) or products, including those made by Juul, are required by law to obtain FDA authorization in order to be sold legally. During the suspension or review period, authorization for marketing, sales, or transportation of Juul products is not implied.
In June, the FDA ordered Juul to stop marketing all of its e-cigarette products in the U.S., citing a lack of evidence regarding their safety. However, Juul was granted a temporary stay by a federal appeals court, and has requested an extension to the ban during the appeals process.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
